Screener
Tarsus Pharmaceuticals, Inc. TARS Research and development costs
Research and development costs at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026.
- Filed
- Feb 23, 2026, 4:11 PM EST
- Fiscal year
- FY2025
- Accession
- 0001819790-26-000019
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 |
|---|---|---|
| Deferred tax assets: | ||
| Net operating loss carryforwards | $41,461 | $33,677 |
| Research and development credit carryforwards | 6,986 | 8,642 |
| Capitalized research and development | 7,959 | 21,734 |
| Charitable contributions | 27,692 | 8,842 |
| Intangible assets | 3,575 | 3,658 |
| Stock-based compensation | 6,877 | 4,760 |
| Accruals | 13,638 | 6,764 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s research and development costs?
- Tarsus Pharmaceuticals, Inc. (TARS) reported research and development costs of $7.96M in Q4 2025.
- How has Tarsus Pharmaceuticals, Inc.'s research and development costs changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s research and development costs decreased by 63.4% year-over-year, from $21.73M to $7.96M.
- What does research and development costs mean?
- Research and development costs as reported by Tarsus Pharmaceuticals, Inc. Common Stock.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s research and development costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude